CATB - Catabasis Pharmaceuticals, Inc.
| Previous Close | 6.51 |
| Open | 6.51 |
| Bid | 5.93 x 1300 |
| Ask | 6.30 x 1100 |
| Day's Range | 5.93 - 6.51 |
| 52 Week Range | 4.02 - 9.76 |
| Volume | 211,541 |
| Avg. Volume | 108,098 |
| Market Cap | 71.137M |
| Beta (5Y Monthly) | 1.77 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.58 |
| Earnings Date | Nov 06, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 39.00 |
- Zacks
Catabasis (CATB) Partners with UK-Based Charity for DMD Study
Catabasis (CATB) teams up with Duchenne UK to fund a phase II study of its pipeline candidate edasalonexent, now being developed to treat patients with non-ambulatory Duchenne muscular dystrophy.
- Business Wire
Catabasis Pharmaceuticals and Duchenne UK Announce Partnership to Evaluate Edasalonexent in a Phase 2 Non-Ambulatory Duchenne Muscular Dystrophy Trial
Catabasis and Duchenne UK announce partnership to evaluate edasalonexent in a Phase 2 non-ambulatory Duchenne muscular dystrophy trial
- Simply Wall St.
Is Catabasis Pharmaceuticals, Inc.'s (NASDAQ:CATB) CEO Pay Fair?
Jill Milne became the CEO of Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) in 2008. This analysis aims first to...
- Insider Monkey
Is Catabasis Pharmaceuticals Inc (CATB) A Good Stock To Buy?
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]
- Business Wire
Catabasis Pharmaceuticals Announces Phase 3 PolarisDMD Trial Enrolled Expected Patient Population
Catabasis Pharmaceuticals announces Phase 3 PolarisDMD trial enrolled expected patient population
- Thomson Reuters StreetEvents
Edited Transcript of CATB earnings conference call or presentation 7-Nov-19 1:30pm GMT
Q3 2019 Catabasis Pharmaceuticals Inc Earnings Call
- Simply Wall St.
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB): What Does Its Beta Value Mean For Your Portfolio?
If you're interested in Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), then you might want to consider its beta (a...
- Business Wire
Catabasis Pharmaceuticals Reports Third Quarter 2019 Financial Results and Reviews Business Progress
-- Edasalonexent Global Phase 3 PolarisDMD Trial in Duchenne Muscular Dystrophy Fully Enrolled with Top-Line Results Expected in Q4 2020 --
- Business Wire
Catabasis Pharmaceuticals to Present Third Quarter 2019 Financial Results and Recent Corporate Developments on Thursday, November 7th
Catabasis Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, will report third quarter 2019 financial results before the Nasdaq Global Market open on Thursday, November 7, 2019.
- Simply Wall St.
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB): When Will It Breakeven?
Catabasis Pharmaceuticals, Inc.'s (NASDAQ:CATB): Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical...
- Business Wire
Catabasis Pharmaceuticals to Present at the Child Neurology Society 48th Annual Meeting
Catabasis Pharmaceuticals, Inc. (CATB), a clinical-stage biopharmaceutical company, today announced that results from the Phase 2 MoveDMD trial and open-label extension with edasalonexent in boys affected by Duchenne muscular dystrophy (DMD) will be presented at the Child Neurology Society 48th Annual Meeting to be held October 23-26 in Charlotte, North Carolina. Richard Finkel, M.D., Chief, Division of Neurology, Department of Pediatrics at Nemours Children’s Health System and a Principal Investigator for the Phase 2 MoveDMD and Phase 3 PolarisDMD studies of edasalonexent, will give an oral presentation titled “Treatment of Young Boys with Duchenne Muscular Dystrophy with the NF-kB Inhibitor Edasalonexent Showed a Slowing of Disease Progression as Assessed by MRI and Functional Measures” during Platform Session 1 on Friday, October 25th at 9:00am ET.
- Business Wire
Catabasis Pharmaceuticals Presents Edasalonexent, a Potential Foundational Treatment for Duchenne Muscular Dystrophy
Catabasis Pharmaceuticals, Inc. (CATB), a clinical-stage biopharmaceutical company, today presented the findings from the MoveDMD trial of edasalonexent. In the Phase 2 MoveDMD trial and open-label extension, edasalonexent slowed disease progression compared to the off-treatment control period and was well tolerated through more than 55 cumulative patient years of exposure in boys affected by Duchenne muscular dystrophy (DMD). “Our goal is to provide a therapy for DMD that slows disease progression, has a compelling safety profile and can be used in boys regardless of mutation,” said Joanne Donovan, M.D., Ph.D., Chief Medical Officer of Catabasis.
- Business Wire
Catabasis Pharmaceuticals Announces the Phase 3 PolarisDMD Trial of Edasalonexent in Duchenne Muscular Dystrophy has Exceeded Target Enrollment
Catabasis Pharmaceuticals, Inc. (CATB), a clinical-stage biopharmaceutical company, announced today the completion of enrollment for the Phase 3 PolarisDMD trial of edasalonexent in Duchenne muscular dystrophy (DMD). Top-line results from the Phase 3 PolarisDMD trial are expected in the fourth quarter of 2020 and the trial is anticipated to support an NDA filing in 2021. At a time when there are multiple trials for Duchenne, we are very pleased that physicians and families chose the Phase 3 PolarisDMD trial for edasalonexent,” said Joanne Donovan, M.D., Ph.D., Chief Medical Officer of Catabasis.
- Simply Wall St.
How Much Of Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) Do Institutions Own?
A look at the shareholders of Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) can tell us which group is most powerful...
- Simply Wall St.
Investors Who Bought Catabasis Pharmaceuticals (NASDAQ:CATB) Shares Three Years Ago Are Now Down 87%
It's not possible to invest over long periods without making some bad investments. But you want to avoid the really...
- Thomson Reuters StreetEvents
Edited Transcript of CATB earnings conference call or presentation 8-Aug-19 12:30pm GMT
Q2 2019 Catabasis Pharmaceuticals Inc Earnings Call
- Simply Wall St.
Does Catabasis Pharmaceuticals, Inc.'s (NASDAQ:CATB) CEO Pay Reflect Performance?
Jill Milne became the CEO of Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) in 2008. This analysis aims first to...
- Business Wire
Catabasis Pharmaceuticals Provides Update on Global Phase 3 PolarisDMD Trial for Edasalonexent at Parent Project Muscular Dystrophy 25th Annual Conference
Catabasis Pharmaceuticals, Inc. (CATB), a clinical-stage biopharmaceutical company, shared an update on the clinical development of edasalonexent, a novel NF-kB inhibitor for the treatment of Duchenne muscular dystrophy (DMD) this week at the Parent Project Muscular Dystrophy (PPMD) 25th Annual Conference. Screening is ongoing for the randomized, double-blind, placebo-controlled trial in the United States, Canada, Australia, the United Kingdom, Ireland, Sweden, Germany and Israel and making strong progress. Clinical trial sites globally are enrolling quickly and sites in the United Kingdom, Ireland, Sweden, Germany and Israel are at capacity and no longer accepting additional patients.
